

Notoginsenoside R1

Chemical Properties

CAS No. :	80418-24-2
Formula:	C47H80O18
Molecular Weight:	933.13
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	Notoginsenoside R1 (Sanchinoside R1) has been shown to exhibit antioxidant, antiapoptotic, anti-inflammatory, and immune-stimulatory properties.
Targets(IC50)	Apoptosis,ERK,Beta Amyloid
In vitro	<p>METHODS: Human colorectal cancer cells HCT-116 were treated with Notoginsenoside R1 (75-300 μM) for 48 h. Cell viability was measured by MTT assay.</p> <p>RESULTS: Cell viability of HCT-116 cells treated with 75-300 μM Notoginsenoside R1 was not significantly different from that of the control. However, treatment with 500 μM Notoginsenoside R1 for 48 h resulted in a significant decrease in cell viability (58\pm7.26%) compared to control cells. [1]</p> <p>METHODS: Human coronary artery smooth muscle cells hCASMCM were treated with Notoginsenoside R1 (10 μM) for 24 h. The cells were stimulated with 10% FBS for 0-30 min, and the expression levels of target proteins were detected by Western Blot.</p> <p>RESULTS: Akt phosphorylation in hCASMCMs was rapidly reduced in a time- and dose-dependent manner after Notoginsenoside R1 treatment, but no effect on ERK1/2 and JNK signaling was observed. Notoginsenoside R1 caused a modest reduction in p38 MAPK phosphorylation, but this did not reach significance. [2]</p>
In vivo	<p>METHODS: To study the effect on neoplastic endothelial hyperplasia, Notoginsenoside R1 (10 mg/kg) was administered intraperitoneally to C57BL/6 J mice once daily for three weeks. A mouse femoral artery injury model was subsequently performed.</p> <p>RESULTS: Notoginsenoside R1 attenuated neointimal formation after femoral artery injury in vivo. Notoginsenoside R1 treatment reduced neointimal formation by inhibiting VSMC proliferation. [2]</p>

Solubility Information

Solubility	H2O: 2.5 mg/mL (2.68 mM),Sonication is recommended. DMSO: 247.5 mg/mL (265.24 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 2.5 mg/mL (2.68 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may</i>

A DRUG SCREENING EXPERT

In vivo Formulation	<i>vary and should be modified based on specific experimental conditions.</i>
---------------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.0717 mL	5.3583 mL	10.7166 mL
5 mM	0.2143 mL	1.0717 mL	2.1433 mL
10 mM	0.1072 mL	0.5358 mL	1.0717 mL
50 mM	0.0214 mL	0.1072 mL	0.2143 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Lee CY, et al. Inhibition of human colorectal cancer metastasis by notoginsenoside R1, an important compound from Panax notoginseng. *Oncol Rep.* 2017 Jan;37(1):399-407.

Chen Z, Ni R, Hu Y, et al. A natural protopanaxatriol from Panax notoginseng enhances osteosarcoma sensitivity to ferroptosis via ASCL4 upregulation. *Journal of Functional Foods.* 2024, 122: 106488.

Fang H, et al. Notoginsenoside R1 inhibits vascular smooth muscle cell proliferation, migration and neointimal hyperplasia through PI3K/Akt signaling. *Sci Rep.* 2018 May 15;8(1):7595.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481